PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-64.40%
Both companies show declining cash positions (-64.40% vs TRVN's -17.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Cash + STI yoy ≥ 1.5x TRVN's -17.75%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
≥ 1.5x TRVN's -18.28%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
≥ 1.5x TRVN's -16.37%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
289.39%
Less than half of TRVN's -18.90%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Similar yoy changes to TRVN's 100.00%. Walter Schloss finds parallel near-term liability trends.
357.80%
Above 1.5x TRVN's 16.90%. Michael Burry sees a red flag for liquidity risk vs. competitor.
8.45%
Less than half of TRVN's -100.00%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Less than half of TRVN's -0.77%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
40.87%
Above 1.5x TRVN's 1.42%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-9.75%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
-29.17%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-61.26%
≥ 1.5x TRVN's -22.96%. David Dodd sees stronger capital base growth than competitor.
-64.40%
≥ 1.5x TRVN's -16.37%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
8.45%
Less than half of TRVN's -94.51%. David Dodd sees less overall debt expansion vs. competitor.
24.32%
Less than half of TRVN's -156.99%. David Dodd sees better deleveraging or stronger cash buildup than competitor.